C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT

C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment

Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).

Inclusion Criteria:

• at least 20 years of age
• previously untreated
• complete pre-treatment clinical staging including bone marrow examination
• written informed consent to participate in the study

Exclusion Criteria:

• concurrent active malignant tumor(s)
• pregnant or breast feeding women
• non-compliant to PET/CT or to MRI
• marked renal impairment (contraindicated for contrast-enhanced MRI)